AstraZeneca’s Lung Portfolio Diverges: Two Phase III Wins, One Discontinuation

Company: AstraZeneca · Event Type: Three Phase III Topline Disclosures · Assets: Osimertinib + Savolitinib (SAFFRON) · Trastuzumab Deruxtecan (DESTINY-Lung04) · Volrustomig (eVOLVE-Lung02) · Indication: Non-Small Cell Lung Cancer · Disclosure Date: August 17, 2026 Summary AstraZeneca disclosed three divergent Phase III lung-cancer outcomes on…